Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A.
Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy.
Moody TW, Lee L, Ramos-Alvarez I, Iordanskaia T, Mantey SA, Jensen RT.
Front Endocrinol (Lausanne). 2021 Sep 1;12:728088. doi: 10.3389/fendo.2021.728088. eCollection 2021.
PMID:34539578
Central nervous system (CNS) neuroblastoma. A case-based update.
Bianchi F, Tamburrini G, Gessi M, Frassanito P, Massimi L, Caldarelli M.
Childs Nerv Syst. 2018 May;34(5):817-823. doi: 10.1007/s00381-018-3764-3. Epub 2018 Mar 8.
PMID:29520437
H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?
Gessi M, Gielen GH, Hammes J, Dörner E, Mühlen AZ, Waha A, Pietsch T.
J Neurooncol. 2013 Mar;112(1):67-72. doi: 10.1007/s11060-012-1040-z. Epub 2013 Jan 26.
Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature.
Benesch M, Sperl D, von Bueren AO, Schmid I, von Hoff K, Warmuth-Metz M, Ferrari R, Lassay L, Kortmann RD, Pietsch T, Rutkowski S.
J Neurooncol. 2011 Aug;104(1):279-86. doi: 10.1007/s11060-010-0485-1. Epub 2010 Dec 22.
PMID:21181235
Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma.
Miller S, Rogers HA, Lyon P, Rand V, Adamowicz-Brice M, Clifford SC, Hayden JT, Dyer S, Pfister S, Korshunov A, Brundler MA, Lowe J, Coyle B, Grundy RG.